Journey Medical Corporation DERM
- Market cap
- $178.4M
- P/E
- 0.0×
Follow DERM
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | 5.12 | 1.05 | 1.02 | 2.85 | 3.54 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | — | 10.20 | 6.19 | 8.11 | 6.89 | 9.40 |
High Price
|
|||
| — | — | — | — | 82 | 90 | 80 | 58 | 41 | 58 |
Employees
|
|||
| — | — | — | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
Revenue/Emp
|
|||
| — | — | — | 35 | 45 | 63 | 74 | 79 | 56 | 62 |
Revenue
|
|||
| — | — | — | 69.84% | 67.23% | 49.18% | 58.23% | 71.09% | 62.81% | 66.17% |
Gross Margin
|
|||
| — | — | — | 5 | 7 | (42) | (30) | (4) | (15) | (11) |
EBT
|
|||
| — | — | — | 14.33% | 16.06% | (67.10%) | (40.13%) | (4.59%) | (26.03%) | (18.38%) |
EBT Margin
|
|||
| — | 0 | — | 4 | 5 | (44) | (30) | (4) | (15) | (11) |
Net Income
|
|||
| — | — | — | 1 | 2 | 5 | 4 | 7 | 4 | 5 |
Depreciation
|
|||
| — | — | — | 3.82 | 4.87 | 6.20 | 4.20 | 4.34 | 2.75 | 2.53 |
Revenue/Sh
|
|||
| — | — | — | 0.40 | 0.58 | (4.32) | (1.69) | (0.21) | (0.72) | (0.47) |
Earnings/Sh
|
|||
| — | — | — | 0.99 | 0.56 | (0.21) | (0.77) | 0.29 | (0.45) | (0.51) |
Cash Flow/Sh
|
|||
| — | — | — | (0.26) | (0.13) | (0.98) | (1.14) | (0.27) | (0.73) | 0.00 |
Capex/Sh
|
|||
| — | — | — | 0.72 | 0.43 | (1.20) | (1.91) | 0.01 | (1.18) | (0.51) |
Free CF/Sh
|
|||
| — | — | — | 0.30 | 1.13 | 4.13 | 0.97 | 1.12 | 0.98 | 1.30 |
Book Value/Sh
|
|||
| — | — | — | 9 | 9 | 10 | 18 | 18 | 20 | 24 |
Shares
|
|||
| — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | — | 1.65 | 1.65 | 0.87 | 0.44 | 1.25 | 1.42 | 3.05 |
PS Ratio
|
|||
| — | — | — | 0.00 | 0.00 | 1.30 | 1.90 | 4.86 | 3.98 | 5.93 |
PB Ratio
|
|||
| — | — | — | 1.61 | 1.61 | 0.16 | 0.31 | 1.13 | 1.56 | 3.16 |
EV/Sales
|
|||
| — | — | — | 14.56 | 14.56 | (0.77) | (0.69) | 372.00 | (3.63) | (7.13) |
EV/FCF
|
|||
| — | — | — | 9 | 5 | (2) | (14) | 5 | (9) | (12) |
Op' Cash Flow
|
|||
| — | — | — | (2) | (1) | (10) | (20) | (5) | (15) | 0 |
Capex
|
|||
| — | — | — | 7 | 4 | (12) | (34) | 0 | (24) | (12) |
FCF
|
|||
| — | — | — | 4 | 7 | 33 | 11 | 15 | 13 | 29 |
Working Cap'
|
|||
| — | — | — | 5 | 10 | 4 | 23 | 15 | 25 | 25 |
Total Debt
|
|||
| — | — | — | 1 | 2 | (45) | (9) | (13) | 5 | 1 |
Net Debt
|
|||
| — | — | — | 3 | 10 | 42 | 17 | 20 | 20 | 32 |
Sh' Equity
|
|||
| — | — | — | 21.41% | 12.32% | (58.98%) | (29.27%) | (4.23%) | (18.68%) | (13.08%) |
ROA
|
|||
| — | — | — | 101.01% | 41.33% | 0.00% | (221.83%) | (17.20%) | (34.69%) | (15.46%) |
ROIC
|
|||
| — | — | — | 55.58% | 81.00% | (168.12%) | (100.39%) | (20.64%) | (72.60%) | (44.03%) |
ROE
|
|||
Journey Medical Corporation peers in Drug Manufacturers Specialty & Generic
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| LFCR Lifecore Biomedical, Inc. | $162.4M | 0.0× | Compare |
| CRDL Cardiol Therapeutics Inc. | $202.1M | 0.0× | Compare |
| OGI Organigram Global Inc. | $155.1M | 2.4× | Compare |
| ORGO Organogenesis | $207.1M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| SIGA Siga Technologies Inc. | $233.5M | 0.0× | Compare |
| AKBA Akebia Therapeutics, Inc. | $254.7M | 0.0× | Compare |
| CPIX Cumberland Pharmaceuticals Inc. | $120.0M | 0.0× | Compare |
| ACB Aurora Cannabis Inc. | $267.8M | 0.0× | Compare |
Journey Medical Corporation (DERM) key facts
- Journey Medical Corporation (DERM) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
- Journey Medical Corporation’s revenue for fiscal 2025 (year ended December 2025) was $61.9 million, up 10.2% from fiscal 2024.
- Journey Medical Corporation reported a net loss of $11.4 million, or a loss of $0.47 per share, for fiscal 2025.
- As of September 25, 2026, DERM traded at $6.14, a market capitalization of $178.4 million.
- Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 2.5× sales.
- Return on equity was −44.0% and debt-to-equity 0.79.
Journey Medical Corporation (DERM) Latest News
21 Sep
Journey Medical DERM shows unusually high implied volatility in the Sep 18, 2026 $50 call, signaling a market expectation of a large move. Implied volatility reflects anticipated price swings and may hint at upcoming catalysts or a big rally or selloff. Fundamentals remain weak: Zacks ranks DERM #4 Sell in Medical – Drugs, with analysts trimming current-quarter estimates from 9 cents to 2 cents per share. With a bleak near-term outlook, some traders may sell premium on high-IV options to profit from time decay if the stock doesn't move as much as expected. The piece hints at an options-driven setup despite lackluster fundamentals. Elevated implied volatility amid weak fundamentals suggests near-term price moves driven more by options activity than by substantive business catalysts.
19 Aug
Journey Medical (DERM) released its Q2 2026 earnings call transcript covering financial results, operational updates and outlook. Q2 2026 earnings details directly affect investor views and DERM stock movement.
13 Aug
Journey Medical Corp reported Emrosi surging 20% sequentially during its Q2 2026 earnings call. Emrosi 20% sequential sales growth indicates strong commercial momentum likely to lift revenue trajectory and investor sentiment.
12 Aug
Journey Medical Corporation held its Q2 2026 earnings call, covering quarterly financial results, operational updates, and forward-looking guidance for DERM. Quarterly earnings calls deliver financial metrics and outlook that can shift near-term investor sentiment and stock performance.
Fortress Biotech Q2 earnings call covered financial results and subsidiary updates including Journey Medical (DERM) product performance and pipeline progress. Earnings call delivered operational and financial updates on DERM that may moderately affect near-term sentiment and performance.
Journey Medical Corporation held its Q2 earnings call, highlighting financial results, operational updates and future outlook for the company. Q2 earnings call delivers financial and strategic updates that moderately influence company performance and investor views.
Journey Medical Corporation reported a Q2 loss and missed revenue estimates. Q2 loss and revenue miss directly affects financial performance and near-term stock sentiment.
Journey Medical Corporation reported second quarter 2026 financial results and recent corporate highlights. Quarterly financial results reporting can moderately influence short-term stock performance and investor views.
14 May
Journey Medical Corporation (DERM) Q1 2026 earnings call summary covers financial results, operational updates, and forward guidance for the dermatology-focused pharmaceutical company. Earnings call summaries reveal quarterly financials and strategic outlook, significantly impacting DERM's market performance and investor confidence.
Journey Medical Corp (DERM) reported Q1 2026 revenue growth and strategic initiatives in earnings call highlights. Q1 revenue growth and strategic developments represent major positive shifts in financial performance and competitive positioning for DERM.
13 May
Journey Medical Corporation (DERM) released its Q1 2026 earnings call transcript detailing quarterly financial results, operational updates, and management's outlook. Q1 2026 earnings transcript discloses financial performance and strategic guidance with potential to significantly sway investor sentiment and stock trajectory.
Journey Medical Corporation (DERM) released the transcript of its Q1 2026 earnings conference call, detailing quarterly financial results, operational updates, and forward-looking guidance. Q1 2026 earnings transcript reveals financial performance, strategic updates, and guidance that significantly shape investor sentiment and stock trajectory for DERM.
Journey Medical Corporation (DERM) reported first quarter 2026 financial results and recent corporate highlights. Quarterly financial results and corporate highlights directly impact investor sentiment, stock valuation, and future trajectory.
Key metrics from Journey Medical Corporation (DERM) Q1 earnings provide critical insights into the company's financial performance. Q1 earnings key metrics analysis moderately influences Journey Medical's financial performance and investor sentiment.
Journey Medical Corporation (DERM) reported a Q1 net loss but beat revenue estimates. Quarterly loss with revenue beat affects financial performance and market sentiment moderately.
6 May
Journey Medical Corporation (DERM) is projected to report negative Q1 earnings per share of -$0.16, missing estimates, amid declining year-over-year revenues and key factors like product sales trends and expense management that investors should monitor ahead of the earnings release. Projected negative Q1 earnings directly threaten DERM's short-term financial results and stock performance.
21 Apr
Journey Medical Corporation secures contract with its third major GPO for Emrosi™, expanding distribution of the rosacea treatment through powerful group purchasing networks. Contract with third major GPO significantly boosts Emrosi™ market access and sales potential for Journey Medical.
29 Mar
Journey Medical Corporation (DERM) narrative shifts as analysts issue new price targets amid substantial going concern risks signaling potential financial distress and operational challenges. Going concern risks combined with new analyst targets indicate major threats to financial stability and investor confidence.
26 Mar
Journey Medical Corporation (DERM) Q4 earnings key metrics compared to estimates, highlighting performance against expectations. Q4 earnings metrics versus estimates signal potential shifts in financial health and investor confidence.
Journey Medical Corporation's Q4 2025 earnings call summary details financial results, operational highlights, and forward guidance for DERM. Q4 year-end earnings summary provides critical financial data and outlook that could drive significant shifts in DERM's valuation and investor confidence.
25 Mar
Journey Medical Corp (DERM) Q4 2025 earnings call highlights strong revenue growth. Strong revenue growth in Q4 2025 earnings call indicates significant positive impact on DERM's financial performance and investor sentiment.
Journey Medical Corporation (DERM) released Q4 earnings call highlights, covering financial results, revenue growth, product performance in dermatology, operational updates, and forward guidance. Q4 earnings highlights disclose key financial metrics, pipeline progress, and outlook that could substantially shape investor expectations and market performance.
Journey Medical Corporation (DERM) reported full-year 2025 financial results and recent corporate highlights. Full-year financial results and corporate highlights signal major updates on performance and strategy, likely shifting investor sentiment and trajectory.
8 Jan
Journey Medical Corporation announced positive results from its Phase 1 clinical trial of Emrosi, a microbiome-based treatment. The data indicates that Emrosi is well-tolerated and shows promising efficacy in treating skin conditions. This development is expected to advance the company's product pipeline and enhance its position in the dermatology market. Positive Phase 1 data for Emrosi could significantly influence Journey Medical's product development and market positioning.
10 Dec
Journey Medical Corporation announced the publication of clinical trial results in the Journal of Drugs in Dermatology, which assessed the impact of Emrosi™ (DFD-29) on the microbial flora of healthy adults. The study's findings are expected to contribute to the understanding of Emrosi™'s effects and its potential applications in dermatology. The publication of clinical trial results may moderately influence Journey Medical Corporation's competitive positioning and product innovation in the dermatology market.
19 Nov
Journey Medical Corporation (DERM) is positioned as a promising investment due to its innovative dermatology products and strategic growth initiatives. The company focuses on expanding its product portfolio and enhancing market presence, which could lead to increased revenue and shareholder value. Recent developments indicate a commitment to addressing unmet medical needs in dermatology, potentially attracting investor interest and improving market performance. Significant growth initiatives and product expansions are likely to alter the company's trajectory and investor sentiment.
17 Nov
Journey Medical Corporation (DERM) reported strong revenue growth in Q3 2025, highlighting significant advancements in its product offerings and market presence. The company emphasized its commitment to innovation and expanding its portfolio, which contributed to improved financial performance. Management expressed optimism about future growth prospects and strategic initiatives aimed at enhancing shareholder value. Strong revenue growth and strategic initiatives indicate a significant impact on future performance and investor sentiment.
12 Nov
Journey Medical Corporation (DERM) reported its Q3 earnings, which fell short of analysts' expectations. Key metrics highlighted a decline in revenue and an increase in operational costs, raising concerns about the company's financial health. Despite these challenges, management remains optimistic about future growth prospects and ongoing product development initiatives. Earnings performance and operational cost increases may moderately influence financial outlook and market sentiment.
Journey Medical Corporation (DERM) reported a loss in Q3, falling short of revenue estimates. The company's financial performance has raised concerns among investors, as it struggles to meet market expectations. This disappointing report may impact investor sentiment and the company's future outlook. The Q3 loss and revenue shortfall may moderately affect financial performance and investor confidence.
Journey Medical Corporation reported its financial results for the third quarter of 2025, highlighting key metrics such as revenue growth and operational achievements. The company emphasized recent corporate developments, including advancements in product offerings and strategic initiatives aimed at enhancing market presence. Overall, the report reflects a positive trajectory for Journey Medical as it navigates the competitive landscape in the medical sector. The financial results and corporate highlights indicate moderate improvements that may influence the company's performance but are not expected to drastically change its overall trajectory.